BR112015010119A2 - composição farmacêutica que contém um inibidor de ace e um bloqueador do canal de cálcio - Google Patents

composição farmacêutica que contém um inibidor de ace e um bloqueador do canal de cálcio

Info

Publication number
BR112015010119A2
BR112015010119A2 BR112015010119A BR112015010119A BR112015010119A2 BR 112015010119 A2 BR112015010119 A2 BR 112015010119A2 BR 112015010119 A BR112015010119 A BR 112015010119A BR 112015010119 A BR112015010119 A BR 112015010119A BR 112015010119 A2 BR112015010119 A2 BR 112015010119A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
calcium channel
channel blocker
ace inhibitor
composition containing
Prior art date
Application number
BR112015010119A
Other languages
English (en)
Inventor
Turczyn Elzbieta
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49724636&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015010119(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of BR112015010119A2 publication Critical patent/BR112015010119A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1/1 resumo composição farmacêutica que contém um inibidor de ace e um bloqueador do canal de cálcio expõe-se uma composição farmacêutica sob a forma de uma mistura que consiste de a) um pó que contém um inibidor de ace, e b) um granulado que contém um bloqueador do canal de cálcio, em que o pó a) e o granulado b) contêm um ou mais excipientes. a composição é de utilidade no tratamento de condições relacionadas com hipertensão.
BR112015010119A 2012-11-15 2013-11-12 composição farmacêutica que contém um inibidor de ace e um bloqueador do canal de cálcio BR112015010119A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL401632A PL227900B1 (pl) 2012-11-15 2012-11-15 Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
PCT/IB2013/060069 WO2014076632A1 (en) 2012-11-15 2013-11-12 A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker

Publications (1)

Publication Number Publication Date
BR112015010119A2 true BR112015010119A2 (pt) 2017-07-11

Family

ID=49724636

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010119A BR112015010119A2 (pt) 2012-11-15 2013-11-12 composição farmacêutica que contém um inibidor de ace e um bloqueador do canal de cálcio

Country Status (18)

Country Link
EP (1) EP2919815B1 (pt)
AU (1) AU2013346397B2 (pt)
BR (1) BR112015010119A2 (pt)
EA (1) EA027568B1 (pt)
ES (1) ES2650468T3 (pt)
HK (1) HK1213807A1 (pt)
HR (1) HRP20171863T1 (pt)
HU (1) HUE035163T2 (pt)
MX (1) MX353689B (pt)
MY (1) MY170451A (pt)
PH (1) PH12015501036B1 (pt)
PL (2) PL227900B1 (pt)
PT (1) PT2919815T (pt)
RS (1) RS56664B1 (pt)
SG (1) SG11201503441XA (pt)
UA (1) UA114439C2 (pt)
WO (1) WO2014076632A1 (pt)
ZA (1) ZA201504265B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275432A1 (en) * 2016-07-25 2018-01-31 H e x a l Aktiengesellschaft Dosage form with ace inhibitor
WO2021162562A2 (en) * 2020-02-10 2021-08-19 Adamed Pharma S.A. Stable ramipril composition and fixed dose composition comprising thereof
GB2595203A (en) * 2020-03-03 2021-11-24 Alkaloid Ad Skopje Formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5093129A (en) 1989-01-30 1992-03-03 E. R. Squibb & Sons, Inc. Method for treating addiction to a drug of abuse employing an ace inhibitor
BR0003282A (pt) 2000-07-14 2002-02-26 Libbs Farmaceutica Ltda Associação farmacêutica para tratamento da hipertenção arterial e prevenção de doenças cardiovasculares outras, como infarto do miocárdio, acidente vascular cerebral e insuficiências cardìaca e renal
CA2357982A1 (en) 2001-09-28 2003-03-28 Bernard Charles Sherman Solid compositions comprising ramipril
ATE357933T1 (de) 2002-01-15 2007-04-15 Actavis Group Hf Formulierungen von quinapril und verwandte ace- hemmer
US20030215526A1 (en) 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
US20050181055A1 (en) 2003-10-08 2005-08-18 Mathur Rajeev S. Pharmaceutical compositions of quinapril
EA011712B1 (ru) 2004-03-29 2009-04-28 Ле Лаборатуар Сервье Способ производства твёрдой фармацевтической композиции
HUP0401170A2 (en) * 2004-06-10 2006-09-28 Richter Gedeon Vegyeszet Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for
US10130624B2 (en) 2005-03-15 2018-11-20 Lupin Limited Pharmaceutical compositions of amlodipine and benazepril
AU2005336956A1 (en) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
EP1948136A1 (en) 2005-11-07 2008-07-30 King Pharmaceuticals Research and Development, Inc. Compositions of stabilized ramipril in combination with another active agent
WO2008065485A2 (en) 2006-10-19 2008-06-05 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor
CN102781430B (zh) 2010-02-24 2015-09-09 赛诺菲-安万特德国有限公司 雷米普利和苯磺酸氨氯地平的固体药物制剂、及其制备

Also Published As

Publication number Publication date
PL227900B1 (pl) 2018-01-31
EA027568B1 (ru) 2017-08-31
UA114439C2 (uk) 2017-06-12
AU2013346397A1 (en) 2015-06-18
ES2650468T3 (es) 2018-01-18
ZA201504265B (en) 2017-11-29
HUE035163T2 (en) 2018-05-02
PT2919815T (pt) 2017-12-11
HK1213807A1 (zh) 2016-07-15
EP2919815A1 (en) 2015-09-23
RS56664B1 (sr) 2018-03-30
EA201590529A1 (ru) 2015-09-30
WO2014076632A1 (en) 2014-05-22
MX353689B (es) 2018-01-23
PL2919815T3 (pl) 2018-01-31
PH12015501036A1 (en) 2015-08-17
PL401632A1 (pl) 2014-05-26
MY170451A (en) 2019-07-31
AU2013346397B2 (en) 2017-09-14
SG11201503441XA (en) 2015-05-28
PH12015501036B1 (en) 2015-08-17
EP2919815B1 (en) 2017-09-06
MX2015006122A (es) 2015-08-05
HRP20171863T1 (hr) 2018-01-12

Similar Documents

Publication Publication Date Title
SA519401897B1 (ar) [4، 5-d][1،3] 4h مركبات 7-فينيل إيثيل أمينو--بيريميدو أكسازين-2-ون كمثبطات أيزو سيترات ديهيدروجيناز 1 وأيزو سيترات ديهيدروجيناز 2 الطافر
PH12016500024A1 (en) Bromodomain inhibitor
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
PH12016500170A1 (en) Formulation of syk inhibitors
GT201400111A (es) Triazolopiridinas sustituidas
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
PH12018500378A1 (en) Novel annelated phenoxyacetamides
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
EA031679B9 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
TR201004464A2 (tr) Kemik erimesi için formülasyon.
CL2008003602A1 (es) Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos.
BR112015010119A2 (pt) composição farmacêutica que contém um inibidor de ace e um bloqueador do canal de cálcio
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
BR112016014523A2 (pt) Composições de higiene oral e uso
CL2012000350A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl.
BR112015025101A2 (pt) composição antitumoral que compreende um inibidor pi3kbeta-seletivo e um inibidor pi3kalfa-seletivo
TN2013000137A1 (en) Pharmaceutical compositions containing a dgat 1 inhibitor
MX2012006194A (es) Composiciones analgesicas que comprenden quercetina mas ketorolaco.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2493 DE 16/10/2018.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI